Immune Defense Protein's effect on cold and flu symptoms in older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a consumer-driven, decentralized observational study that follows adults 60 and older who have chosen to try the IDP® supplement. Participants report symptoms, medication use, quality of life, and tolerability using surveys in the Chloe smartphone app while product is shipped to their home. The study compares self-reported duration and severity of upper respiratory symptoms across product groups (two IDP doses and a matching placebo) and tracks rescue medication use and daily activities. All data are collected remotely through participant-reported outcome measures completed at home.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 60 years and older
2. Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
3. Able to read and understand English.
4. Able to read, understand, and provide informed consent.
5. Able to use a personal smartphone device and download Chloe by People Science.
6. Able to receive shipment of the product at an address within the United States.

Exclusion Criteria:

Any potential participants who:

1. Do not have a personal smartphone, internet access, or unwilling to download Chloe.
2. Already in an immunocompromised state, including:

   A. Infectious Causes
   * HIV/AIDS
   * Chronic hepatitis B or C (advanced stages)
   * Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
   * Leukemia (e.g., AML, ALL, CLL)
   * Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)
   * Multiple Myeloma
   * Any metastatic cancer receiving chemotherapy

   C. Immunosuppressive Therapy:

   Participants on:
   * Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks)
   * Biologics (e.g., TNF inhibitors like infliximab, adalimumab)
   * Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)
   * mTOR inhibitors (e.g., sirolimus)
   * JAK inhibitors (e.g., tofacitinib)
   * Chemotherapy or radiation therapy
   * Anti-rejection meds post-organ transplant D. Transplant Patients
   * Solid organ transplant (kidney, liver, heart, lung)
   * Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants)
   * Rheumatoid Arthritis
   * Systemic Lupus Erythematosus (SLE)
   * Psoriasis or Psoriatic Arthritis
   * Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis)
   * Multiple Sclerosis (especially on disease-modifying therapies)
3. Other Concomitant Conditions and Therapies:

   1. Any investigational therapies or treatments within 30 days prior to enrollment.
   2. Known diagnosis of Asthma and/or COPD
   3. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
   4. Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes
   5. Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes
4. Use of cannabis-containing products daily
5. Use of nicotine-containing products daily
6. Known hypersensitivity or previous allergic reaction to milk products, Sorbitol and/or tabletting aids.
7. Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.

Where it's running

• People Science, Inc.
  Los Angeles, California, United States Recruiting

Study contacts

• Study coordinator: Noah Craft, M.D., Ph.D
• Email: noah@peoplescience.health
• Phone: 213-328-0919

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Abbott ID NOW at the point of care for flu-like illness in long-term care facilities

  This trial tests whether the Abbott ID NOW rapid test at the point of care in long-term care facilities can help identify influenza sooner for residents 65 and older with fever and respiratory symptoms.

  Recruiting China Medical University Hospital · Taichung · NCT07846423

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Safety and PK of Ingavirin Forte vs Ingavirin in healthy adults under fasting and fed conditions

  This early-phase study tests whether Ingavirin Forte (90 mg + 20 mg) is safe and how it behaves in the body compared with Ingavirin (90 mg) in healthy adults aged 18–45, under different meal conditions.

  Recruiting Phase 1 Valenta Pharm JSC · Saint Petersburg · NCT07645534

• Light-based immune boost to help prevent viral upper respiratory infections

  A daily handheld light therapy device is tested to see if it can lower how often adults at a military medical facility get colds, flu, or other upper respiratory infections.

  Recruiting Mike O'Callaghan Military Hospital · Nellis Air Force Base, Nevada · NCT07610967

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.